Abstract/References

Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine

Yurie Kobashi, Yuzo Shimazu, Takeshi Kawamura, Yoshitaka Nishikawa, Fumiya Omata, Yudai Kaneko, Tatsuhiko Kodama, Masaharu Tsubokura

Author information
  • Yurie Kobashi
    Department of General Internal Medicine, Hirata Central Hospital, Hirata, Ishikawa District
    Department of Radiation Health Management, Fukushima Medical University School of Medicine
  • Yuzo Shimazu
    Department of Radiation Health Management, Fukushima Medical University School of Medicine
    Southern Tohoku Research Institute for Neuroscience
  • Takeshi Kawamura
    Proteomics Laboratory, Isotope Science Center, The University of Tokyo
    Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo
  • Yoshitaka Nishikawa
    Department of General Internal Medicine, Hirata Central Hospital, Hirata, Ishikawa District
  • Fumiya Omata
    Department of General Internal Medicine, Hirata Central Hospital, Hirata, Ishikawa District
  • Yudai Kaneko
    Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo
    Medical & Biological Laboratories Co., Ltd.
  • Tatsuhiko Kodama
    Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo
  • Masaharu Tsubokura
    Department of General Internal Medicine, Hirata Central Hospital, Hirata, Ishikawa District
    Department of Radiation Health Management, Fukushima Medical University School of Medicine

Abstract

This study investigated the immune response and outcome of BNT162b2 vaccination among 12 staff at a hospital in Fukushima, Japan. Blood samples were collected from participants before their first vaccination, with subsequent sampling performed during the participants’ work days for six weeks thereafter. Antibody titers peaked 6-13 days after the second vaccination (days 27-34 after the first), followed by a steady decrease. Six males had significantly lower peak antibody titers than six females (p= 0.016 witht-test); the older six (median age 53 years) had lower antibody titers than the younger six (median age 35 years) but without statistical significance (pvalue=0.24 witht-test).

The content of research paper

References

  1. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet, 397(10286):1725-1735, 2021.
  2. Angel Y, Spitzer A, Henig O, et al. Association between vaccination With BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA, 325(24):2457-2465, 2021.
  3. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA, 325(21):2204-2206, 2021.
  4. Terpos E, Trougakos IP, Apostolakou F, et al. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am J Hematol, 96(7):E257-E259, 2021.
  5. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med, published online Jun 23, 2021. doi:10.1056/NEJMc2108861.

Figures (2)

 

ページの先頭へ戻る